Drug class-action lawsuits
Smith v. Bayer
In brief
The Supreme Court overturned the Eighth Circuit: the federal court could not stop the West Virginia court from considering Smith’s request.
- Where it stands
- Decided
Decided 9-0 · June 16, 2011 · Opinion by Justice Kagan
- What it’s about
- Keith Smith asked a West Virginia court to certify a class of Baycol users, but a federal court barred it from considering his request based on an earlier federal ruling involving a different proposed class.
- Who it affects
- The West Virginia court is not barred from considering Smith’s request, but the Supreme Court did not decide whether the users can proceed as a group.
Summary: written with AI from the case record.
What it's about
The Supreme Court overturned the Eighth Circuit, deciding that the federal court exceeded its authority under an exception for stopping state cases from revisiting issues already decided (the “relitigation exception”) to a federal law that generally bars such orders.
Baycol was a cholesterol-lowering drug removed from the market in 2001. The earlier federal ruling involved a different proposed group of Baycol users.
A federal court relied on an earlier ruling about a different proposed Baycol-users group to stop the West Virginia court from considering Smith’s request.
Question presented
Did a lower court erroneously prevent a group of plaintiffs from proceeding with a class-action lawsuit over a cholesterol-lowering drug that was removed from the market in 2001?
What the Court decided
Holding
In enjoining the state court from considering Smith’s class certification request, the federal court exceeded its authority under the “relitigation exception” to the Act. 593 F. 3d 716, reversed.
- Result
- Reversed
The Court's reasoning
The Court said the federal judge exceeded the authority allowed by an exception to a federal law that generally limits federal orders stopping state cases. That exception did not allow the judge to block the West Virginia court from considering Smith’s request.
The vote
What's next
The West Virginia court may consider Smith’s request. The Supreme Court did not decide whether the court should certify a group of Baycol users.
Documents
Opinions
Audio
Docket activity
New analysis added
AI analysis generated: Case Briefing
New analysis added
AI analysis generated: Impact Analysis
AI analysis generated: Opinion Summary
Show 5 moreShow fewer
AI analysis generated: Decision Record
Case data updated: summary, question_presented, generation_metadata
Case data updated: question_presented, extraction_metadata
Audio Recording added: Oral Arguments - Keith Smith v. Bayer Corporation
Opinion added: Opinion
Sources
Primary materials plus reporting. Best-effort analysis: this explainer relies on a mix of primary materials and trusted secondary sources. Official filings and opinions remain authoritative.